Skip to main content
. 2020 Aug 26;3(8):e2013201. doi: 10.1001/jamanetworkopen.2020.13201

Figure 3. Overall Survival of Patients With MUC16-Mutated vs Wild-Type Tumors Treated With Immune Checkpoint Inhibitors.

Figure 3.

A, Kaplan-Meier curves of overall survival in anti-PD-1/PD-L1–treated patients with non–small cell lung cancer (NSCLC). The median overall survival was 11.3 months (95% CI, 10.1 months to not available) in patients with wild-type tumors and was not reached in patients with MUC16-mutated tumors. B, Kaplan-Meier curves of overall survival in anti-CTLA4–treated patients with melanoma. The median overall survival was 27.03 months (95% CI, 20.07-45.00 months) vs 9.73 months (95% CI, 7.03-15.50 months) in patients with MUC16-mutated and wild-type tumors, respectively.